16 December 2025
Disclaimer: This is a simplified summary of a public company filing. See full disclaimer here.
AMERICAN SHARED HOSPITAL SERVICES
CIK: 744825•2 Annual Reports•Latest: 2025-04-04
10-K / April 4, 2025
Revenue:$28,340,000
Income:$2,200,000
10-K / April 1, 2024
Revenue:$21,325,000
Income:$265,000
10-K / April 4, 2025
Company Summary: American Shared Hospital Services (ASHS)
Business Overview
- Type of Business: Provider of turn-key technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services.
- Main Revenue Drivers:
- Number of sites
- Procedure volume
- Reimbursement rates
Segments
- Medical Equipment Leasing:
- Operates through fee-per-use and revenue sharing contracts
- Shares in revenue and operating costs with hospital/healthcare facilities
- Provides equipment such as Gamma Knife units, LINACs, and PBRT systems
- Leases 9 Gamma Knife systems and 1 PBRT system as of December 31, 2024
- Total leasing sites include U.S. and international locations
- Direct Patient Services ("Retail"):
- Operates facilities directly treating patients in Rhode Island, Peru, Ecuador, and Mexico
- Owns and manages stand-alone Gamma Knife centers in Lima, Peru and Guayaquil, Ecuador
- Owns and operates multiple radiation therapy centers in Rhode Island and Puebla, Mexico
- Started operating a LINAC facility in Puebla, Mexico in July 2024
- Owns 60% in three Rhode Island cancer centers acquired in May 2024
Key Operations & Locations
- Gamma Knife:
- 8 units in the U.S. and 2 units in South America
- Conducted approximately 48,490 procedures through December 31, 2024
- Procedures in 2024: 1,084 (a 9.3% decrease from 2023)
- Revenue from Gamma Knife in 2024: approximately $9.7 million (34.3% of total revenue)
- Proton Beam Radiation Therapy (PBRT):
- 1 PBRT system (located in Orlando, Florida)
- Procedures in 2024: 5,139 (a 4.3% decrease from 2023)
- Revenue in 2024: approximately $9.95 million (about 35% of total revenue)
- Radiation Therapy (LINAC):
- 4 facilities owned and operated as of December 31, 2024
- Began operations at a new LINAC site in Puebla, Mexico in July 2024
- Procedures in 2024: 14,662
- International Operations:
- Facilities in Peru, Ecuador, and Mexico
- Focus on providing Gamma Knife and radiation therapy services
Revenue & Financials (2024)
- Total Revenue: ~$28.34 million (up 32.9% from 2023)
- Leasing segment: $15.6 million (decreased from prior year)
- Retail segment: $12.56 million (significantly increased due to new acquisitions and facilities)
- Gamma Knife services: $9.7 million (34.3% of total revenue)
- PBRT: $9.95 million (35% of total revenue)
- LINAC: $8.5 million (about 30% of total revenue)
- Equipment sales contributed a small amount (~$155,000)
- Net Income (2024): approximately $2.2 million
- Employees: 43 full-time US staff, 15 full-time in Peru, 4 in Ecuador, and 19 in Puebla, Mexico
Customer & Contracts
- Gamma Knife Customers:
- US facilities organized under leasing and revenue-sharing models with hospital and clinic clients
- Top customers accounted for a substantial portion of revenue (two customers 35% and 27% in 2024, and one customer 48% in 2023)
- Leasing contracts typically last 10 years, with no minimum volume guarantees
- International and Domestic Facilities:
- Facilities in Rhode Island, Peru, Ecuador, Mexico
- Owned, leased, or operated directly for patient treatments
Additional Details
- Employees: 43 full-time employees in the US, with additional teams in Peru, Ecuador, and Mexico
- Market & Competition:
- Competes with traditional neurosurgery, radiation, and other radiosurgery devices
- Gamma Knife has a limited market, with a mature US market
- Proton therapy and LINAC are competitive segments with several manufacturers
- Revenue Concentration:
- Significant reliance on a few large customers in both Gamma Knife and leasing segments
- Two customers represented 35% and 27% of revenue in 2024
This summary is based solely on the provided Form 10-K excerpt, including operations, segmentation, revenue, assets, and employee information.
